Conditional Targeting in the Kidney

Fiona Wu
Department of Clinical Sciences, Bristol University, Bristol, UK

Key Words
Kidney-specific targeting • Inducible targeting • Cre/loxP

Abstract
Conditional gene targeting utilising the Cre/loxP system, which allows spatial and temporal control of gene expression, has been increasingly used to study gene function in vivo. The ability to limit gene disruption to a particular cell type and/or to control the timing of gene targeting overcomes some of the limitations associated with conventional targeting and total knockout of a gene, namely, potential embryonic lethality and complicated phenotype affecting multiple tissues. Although the application of this approach to the kidney is relatively recent, it has already proven to enhance our ability to study the developmental, physiological, and pathological processes in the kidney: dissecting the roles of several proteins in complex homeostatic systems, uncovering novel actions of proteins, and establishing models of kidney diseases. As the number of kidney-specific Cre mouse strains increases, this strategy will allow increasingly specific and complicated biological questions in the kidney to be addressed.

Introduction
The similarities in the genetic and cellular functions between mouse and man as well as our ability to manipulate the murine genome by molecular means have led to the widespread use of the mouse as an experimental model to study human disease and development. Gene targeting in mouse embryonic stem (ES) cells by homologous recombination, a process whereby a fragment of exogenously introduced DNA containing the desired mutation locates and recombines with the endogenous homologous sequence, allows direct alterations to be introduced into the mouse genome at a predetermined site [1]. The targeted ES cells are then injected into blastocysts to produce chimeric mice, which are bred to produce animals that are homozygous or heterozygous for the mutated gene. There are two particular limitations with conventional targeting and total knockout of a gene, namely, potential embryonic lethality and complicated phenotype affecting multiple tissues. Although the application of this approach to the kidney is relatively recent, it has already proven to enhance our ability to study the developmental, physiological, and pathological processes in the kidney: dissecting the roles of several proteins in complex homeostatic systems, uncovering novel actions of proteins, and establishing models of kidney diseases. As the number of kidney-specific Cre mouse strains increases, this strategy will allow increasingly specific and complicated biological questions in the kidney to be addressed.
temporal control of gene expression, overcomes some of
these problems and has enhanced our ability to study the
developmental, physiological, and pathological processes
in the kidney.

Tissue-Specific Targeting

The most widely used strategy to limit gene targeting
to specific tissue or cell types utilises the Cre/loxP sys-
tem. The Cre recombinase is a bacteriophage P1 enzyme
that mediates DNA recombination between two appro-
priately configured 34-basepair recognition sequences
(loxP), which results in deletion of the intervening DNA
sequence. In this approach (fig. 1), one transgenic mouse
line, which expresses the Cre recombinase under the
control of a tissue-specific promoter, is crossed with a
second mouse line carrying alleles in which two loxP
sites flank an essential part of the gene to be studied
(‘floxed’ gene). In the offspring that inherits both the Cre
transgene and the floxed alleles, Cre-mediated DNA de-
letion eliminates functional protein expression in cells
expressing the Cre recombinase as determined by the
promoter while leaving the expression of the protein in
other cells intact. The success of kidney-specific target-
ing is dependent on the availability of different Cre trans-
genic lines and the efficiency of the lineage-specific DNA
excision. There are a number of kidney-specific Cre/
targets that have been successfully targeted to date using
the kidney-specific Cre/loxP strategy (table 1) to illustrate
the value of this technology in studying renal biology
and disease.

Regulation of Fluid Balance and Systemic Blood
Pressure

The endothelin (ET) system has been implicated in the
regulation of systemic blood pressure through multiple
mechanisms, and conditional targeting of components of
this complex system has facilitated the process of dissect-
ing their relative contributions and mechanisms of action
[3, 4]. Inactivation of the peptide, ET-1, in the CDs of mice
leads to hypertension, impaired ability to excrete sodium
and water loads, and enhanced vasopressin responsive-
ness [3]. In contrast, disruption of the ET-A receptor in
the CD decreases vasopressin sensitivity but has no effect
on systemic blood pressure or salt balance [4]. Via the in-
hibitory effect of ET-1 on vasopressin action, these stud-
ies suggest that CD-derived ET-1 is a regulator of system-
ic blood pressure with significant natriuretic and diuret-
ic effects in the distal nephron, and ET-A may serve as a
counter-regulatory mechanism to dampen the diuretic
effect of ET-1.

The apical plasma membrane water channel, aquapo-
lin-2 (AQP2), present in the connecting tubules (CNTs)
and in the CD principal cells, is the chief target for regu-
lating the water permeability of these segments by vaso-
pressin. Mice lacking AQP2 in both segments die postna-
tally with severely impaired postnatal kidney develop-
ment, whereas those mice lacking AQP2 expression in
only the CD cells survive to adulthood but show marked
polyuria and severe urinary-concentrating defects [5].
These results demonstrate that AQP2 in CNTs is suffi-
cient for postnatal survival but cannot compensate for
the essential role of AQP2 in the CDs in the regulation of
body water balance. Interestingly, in contrast to the im-
portance of CD function in regulating water balance [5],
specific deletion of the apical epithelial sodium channel
(ENaC) in the cortical CDs of mice does not cause sig-
nificant abnormalities in sodium or potassium balance,
suggesting that only the CNT and late distal convoluted
tubule are quantitatively important in maintaining so-
dium balance [6].

CD-specific inactivation of the nuclear receptor, per-
oxisome proliferator-activated receptor-γ (PPARγ) in
mice provided evidence that ENaC-γ subunit transcrip-
tion and ENaC-mediated sodium reabsorption is PPARγ-
sensitive [7]. It is estimated that 80–90% of the fluid
retention associated with the use of the PPARγ agonist,
thiazolidinedione (TZD), in man is due to enhanced
ENaC-mediated fluid reabsorption in the distal nephron
[7]. These experiments thus revealed a novel action of
PPARγ in the distal nephron and identified a target to
counteract TZD-induced oedema.

Vitamin and Mineral Homeostasis

The endocytic receptor in the proximal tubule (PT),
megalin, is important for the reabsorption of macromol-
ecules filtered by the glomerulus, including several vita-
amin-carrier proteins such as the retinol- and vitamin D-
binding proteins. The conventional megalin-knockout
mice die perinatally from defective forebrain develop-
ment, whereas mice with a kidney-specific megalin de-
fec t develop normally but exhibit multiple defects in vi-
tamin and mineral handling [8–11]. Megalin deficiency
in the PT is associated with low molecular weight pro-
teinuria, increased urinary loss of vitamin D-binding protein and 25-hydroxyvitamin D, systemic hypovitaminosis, hypocalcaemia, and osteomalacia [9]. There is also increased urinary loss of retinol, which is compensated by accelerated mobilisation of hepatic stores to maintain normal plasma retinol levels [10]. Renal phosphate reabsorption, >70% of which is mediated by the type-II sodium phosphate co-transporter (NaPi-IIa) located in the PT brush borders, is also affected [11]. Megalin deficiency in the PT induces ultrastructural altera-

**Fig. 1.** Kidney-specific gene targeting with the Cre/loxP system. Two separate transgenic mouse strains are required to disrupt a gene of interest in a tissue- or cell-specific manner. One strain expresses the Cre recombinase under the control of a kidney-specific promoter and is generated by transgene injection of fertilised oocytes; the other carries two loxP sites flanking a segment of the gene to be studied (‘floxed’) and is generated by homologous recombination in embryonic stem cells. Generally, the loxP sites are located in the introns and flank an essential exon(s) of the gene such that the gene expression is unaffected. The two strains are crossed to produce offspring that carry the Cre transgene and are homozygous for the floxed gene (for simplicity, only one of the two floxed alleles is shown). In these offspring, Cre-mediated DNA deletion in the kidney cells results in the disruption of the target gene exclusively in the renal tissue.
tions in the endocytic apparatus, resulting in enhanced brush border expression of NaPi-IIa and reduced urinary excretion of phosphate in the steady state. The internalisation of NaPi-IIa from the brush border membrane in response to parathyroid hormone is also impaired in the absence of megalin.

### Renal Cystic Disease

A number of mechanisms and genes have been implicated in renal cystogenesis [12–14]. Kidney-specific inactivation of the kinesin II subunit, KIF3A, results in animals with morphologically normal kidneys at birth that progressively develop multiple cysts and renal failure.

### Table 1. Kidney-specific gene targeting

<table>
<thead>
<tr>
<th>Cre mouse</th>
<th>Promoter</th>
<th>Renal expression</th>
<th>Extrarenal expression</th>
<th>Targeted gene inactivation</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AQP2-CreTag</td>
<td>AQP2</td>
<td>CD (principal cells)</td>
<td>Testis, vas deferens</td>
<td>ET-1: Hypertension, salt retention, †vasopressin sensitivity</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ET-A Receptor: Normotension, ‡vasopressin sensitivity</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PPARγ: Renal sodium avidity, resistant to TZD-induced oedema</td>
<td>7</td>
</tr>
<tr>
<td>HoxB7-Cre</td>
<td>Hox-B7</td>
<td>CD, ureter</td>
<td>Developing GUT, spinal cord, dorsal root ganglia</td>
<td>AQP2: Severe urinary concentrating defect</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>α-ENaC: Normal sodium and potassium balance</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Smad4: Normal embryonic CD development; normal phenotype up to age 6 weeks</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Shh: Hypoplasia, hydrenephrosis, and hydrourerter</td>
<td>19</td>
</tr>
<tr>
<td>ApoE-Cre</td>
<td>Human apoE</td>
<td>PT, DT</td>
<td>Not specified</td>
<td>Megalin: Hypovitaminosis, hypocalaemia, osteomalacia, †urinary retinol excretion, ‡phosphaturia</td>
<td>9–11</td>
</tr>
<tr>
<td>Ksp1.3/Cre</td>
<td>Ksp-cadherin</td>
<td>Predominantly CD, TAL</td>
<td>Developing GUT</td>
<td>KIF3A: Polycystic phenotype</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HNF1β: Polycystic phenotype</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>APC: Polycystic phenotype, neonatal lethality, and neoplasm</td>
<td>16</td>
</tr>
<tr>
<td>MMTV-Cre</td>
<td>MMTV LTR</td>
<td>Not specified</td>
<td>Secretory organs</td>
<td>PKD1: Renal and hepatic cysts</td>
<td>14</td>
</tr>
<tr>
<td>PEPCK-Cre</td>
<td>PEPCK</td>
<td>PT</td>
<td>Hepatocytes</td>
<td>VHL: Renal cysts, liver haemangiomas, polycythaemia</td>
<td>15</td>
</tr>
<tr>
<td>AhCre</td>
<td>Cyp1A1</td>
<td>CD, Glom</td>
<td>Not specified</td>
<td>APC: Renal carcinoma</td>
<td>17</td>
</tr>
<tr>
<td>Bmp7&lt;sup&gt;cre&lt;sup&gt;/+&lt;sub&gt;&gt;&lt;/sub&gt;&lt;/sup&gt;</td>
<td>BMP-7</td>
<td>CD, mesenchyme</td>
<td>Developing GUT</td>
<td>Smad4: Defective mesenchymal induction, and organisation</td>
<td>18</td>
</tr>
<tr>
<td>Neph-Cre</td>
<td>Nephrin</td>
<td>Glom (podocytes)</td>
<td>Brain (low)</td>
<td>VEGF-A: Defective glomerular filtration barrier</td>
<td>20</td>
</tr>
<tr>
<td>Inducible Cre mouse</td>
<td>Promoter</td>
<td>Renal expression</td>
<td>Extrarenal expression</td>
<td>Inducer</td>
<td>Targeted gene</td>
</tr>
<tr>
<td>Cre-ERT&lt;sup&gt;TM&lt;/sup&gt;</td>
<td>pCAGGS</td>
<td>Not specified</td>
<td>Ubiquitous</td>
<td>Tamoxifen</td>
<td>Inactivation</td>
</tr>
<tr>
<td>βMCM86</td>
<td>pCAGGS</td>
<td>Glom (podocytes)</td>
<td>Sk and card muscle</td>
<td>Tamoxifen</td>
<td>Activation</td>
</tr>
</tbody>
</table>

Symbols and abbreviations: apoE = apolipoprotein E; APC = adenomatous polyposis coli tumour suppressor; AQP2 = aquaporin-2 water channel; BMP-7 = bone morphogenetic protein7; ETA = endothelin-A; ET-1 = endothelin-1; α-ENaC = epithelial Na<sup>+</sup> channel α-subunit; pCAGGS = CMV-enhanced chicken β-actin; CYP1A1 = cytochrome P4501A1; HNF1β = hepatic nuclear factor 1β; Hox-B = subclass of the Homeobox gene superfamily; KIF3A = kinesin-II subunit; MMTV LTR = mouse mammary tumour virus long terminal repeat; PAX2 = paired box gene 2; PDK1 = polycystic kidney disease 1; PEPCK = phosphoenolpyruvate carboxykinase; PPARγ = peroxisome proliferator-activated receptor subtype γ; Smad4 = mothers against decapentaplegic homolog 4 (Drosophila); Shh = sonic hedgehog; TZD = thiazolidinedione; VEGF-A = vascular endothelial growth factor A; VHL = von Hippel-Lindau tumour suppressor; † = decreased; ‡ = increased; CD = collecting duct; card = cardiac; DT = distal tubule; Glom = glomerulus; GUT = genitourinary tract; PT = proximal tubule; TAL = thick ascending loop of Henle; Sk = skeletal.

1 References for the specific Cre mouse strains used in the targeting studies are contained in the articles cited.

2 Promoters used to control the tissue-specific Cre expression in transgenic mice.

3 Expression of Cre-recombinase in the kidney and other tissues.

Conditional Targeting in the Kidney

Nephron Physiol 2007;107:p10–p16

p13
The cystic epithelial cells lack primary cilia and show altered cellular properties, suggesting a role for the kinesin II tubular motor protein complex in maintaining the normal structure and function of the renal epithelium. Specific inactivation of hepatic nuclear factor-1β in the murine renal epithelium also results in the development of renal cysts [13]. This is accompanied by transcriptional defects and downregulation of protein expression of several cystic disease genes in the cystic epithelium, indicating that dysregulation of the transcription network plays an important role in cystogenesis [13]. Somatic inactivation of the murine homolog of PKD1, mutations of which account for 85% of the patients with autosomal dominant polycystic kidney disease, results in the progressive development of renal and hepatic cysts in the mature animal [14]. This conditional mouse model should thus be invaluable for studying the biological role of polycystin-1, the protein encoded by PKD1, and the pathogenesis of autosomal dominant polycystic kidney disease [14].

Renal Neoplasia

Mutations in the von Hippel-Lindau (VHL) tumour suppressor gene are found in both hereditary and sporadic clear cell renal cell carcinoma (CCRCC), with the former being part of the VHL disease, which is characterised by the development of tumours in multiple organs [15]. Mice with inactivation of the VHL gene in the kidney develop renal cysts, a pathological finding associated with both sporadic and hereditary CCRCC. Furthermore, the renal cysts in these mutant mice show morphological and molecular features with those found in VHL patients [15]. However, these mice do not develop CCRCC, suggesting that while the disruption of the VHL tumour suppressor is critical in renal carcinogenesis, other genetic events are required for the progression of the cysts to carcinoma. Inactivation of the adenomatous polyposis coli (APC) tumour suppressor gene in the murine renal epithelium demonstrated that the loss of the protein and the associated dysregulation of the β-catenin signalling pathway predispose to developing renal carcinoma [16, 17]. In one study, the loss of APC tumour suppressor is associated with early onset polycystic kidney disease and neonatal death in most animals, with the rare surviving individuals developing large, multilayered cysts with features of adenoma or carcinoma in situ [16]. In a separate study, the mutant mice develop multiple dysplastic foci and renal carcinoma [17]. These phenotypic differences probably reflect differences in the two Cre recombinases targeting different cells within the kidney or the shortened life span of the first mouse model precluding progression to carcinoma.

Renal Organogenesis

Normal kidney development depends on the reciprocal interactions between the ureteric bud and the metanephric mesenchyme in the developing genitourinary tract. By selectively disrupting the expression of transcription factor Smad4 in these two cell populations, it was demonstrated that CD development is independent of Smad4, which is a key component of the transforming growth factor-β (TGF-β) signalling pathway [18]. However, the absence of Smad4 in the mesenchyme leads to defective organisation and induction of the nephrogenic mesenchyme, indicating the importance of the TGF-β signalling pathway in early kidney development [18]. Inactivation of the signalling protein, Sonic hedgehog (Shh), in the murine CD epithelium results in renal hypoplasia, hydronephrosis, and hydroureter [19]. In vivo and in vitro analyses showed that Shh acts as a paracrine factor to promote mesenchymal cell proliferation, regulate smooth muscle progenitor cell differentiation, and set the pattern of mesenchymal differentiation [19]. Specific inactivation of the vascular endothelial growth factor-A (VEGF-A) in podocytes revealed that heterozygosity for VEGF-A results in early onset proteinuria and a renal lesion similar to that seen in preeclampsia [20]. Homozygous VEGF-A deletion in the podocytes leads to a failure of glomerular filtration barrier formation and perinatal mortality [20]. These results indicate that tight regulation of VEGF signalling between the podocytes and glomerular endothelium is required for formation and maintenance of the glomerular filtration barrier.

Inducible Targeting

Inducible gene targeting, which allows control of the onset and reversibility of the genetic defect, have several theoretical additional advantages: (1) by timing the gene targeting, potential adverse effects of defective gene function during earlier life can be avoided and also provides a more precise model of disease which develops in adult life; (2) the phenotypes, before and after the gene targeting, act as internal controls and eliminate the need for generating appropriate wild-type controls, which can be time consuming and costly, and (3) reversible gene targeting may demonstrate that the phenotype is clearly associated with the mutated gene, as reversion back to a functional gene should reverse the observed effects.
In the kidney, inducible gene disruption has been developed using ligand-regulated Cre recombinases. Most commonly, the chimeric protein consists of a Cre recombinase fused with a mutant oestrogen receptor ligand-binding domain and its expression is under the control of a kidney-specific promoter [2]. In the absence of the ligand, the Cre is expressed but remains inactive in the cytoplasm, where it is bound to heat shock proteins. Binding of the ligand to the Cre displaces the heat shock proteins and the Cre translocates into the nucleus, where it mediates loxP-flanked DNA excision. The successful application of this system in the kidney has been limited by the efficiency of the Cre-mediated excision. Recently, the first adult mouse model of nephrogenic diabetes insipidus was generated by tamoxifen-induced Cre-mediated AQP2 gene deletion (table 1). In the absence of tamoxifen, the adult Cre-AQP2-loxP mice are phenotypically normal; following tamoxifen treatment, there is a 95% reduction in the AQP2 protein level in the kidney and the mice develop severe polyuria, hypotonic urine, and unresponsiveness to water deprivation [21].

In addition to ablating gene function, conditional targeting can also be used to activate gene function. In this case, Cre-mediated recombination removes a functional barrier to the production of an active gene product, thereby switching on gene expression [22]. Using this approach, a mouse model has been developed which allows inducible activation of Pax2 within the podocytes [22]. Following activation of Pax2, healthy adult mice develop renal disease and proteinuria associated with inhibition of the podocyte key regulator molecule Wt1 and a dramatic reduction in nephrin expression in the glomerulus. This suggests that the ectopic expression of PAX2 in the podocytes plays an important role in the development of glomerular disease [22].

**Conclusion**

Within a relatively short space of time, kidney-specific gene targeting utilising the Cre/loxP system has facilitated studies to dissect out the roles of individual components of several of the complex homeostatic systems operating in the kidney, to uncover novel actions of proteins, and provide important new insights into renal development, physiology, and pathophysiology that have not been possible with more traditional methods. As the number of mouse lines with specific and efficient inducible Cre activity in the different nephron segments and cell types increases, this technology will allow us to ask increasingly more sophisticated and specific biological questions.

**References**


